Vitamin D supplementation and prevention of cardiovascular disease and cancer in the Finnish Vitamin D Trial: a randomized controlled trial.

What Was Tested

This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc.

To investigate the effects of vitamin D3 supplementation on CVD and cancer incidences.

Who Took Part

The study group was 2495 participants.

PubMed indexes the participants as older adults, both men and women.

The study was a 5-year, randomized, placebo-controlled trial among 2495 male participants ≥60 years and post-menopausal female participants ≥65 years from a general Finnish population who were free of prior CVD or cancer.

A representative subcohort of 551 participants had more detailed in-person investigations.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

As a double-blind Vitamin D, K2, Magnesium and Zinc study, the assignments were hidden from both participants and investigators until the end.

Some participants received a placebo instead of Vitamin D, K2, Magnesium and Zinc, giving a reference point.

Follow-up was by annual study questionnaires and national registry data.

The primary endpoints were incident major CVD and invasive cancer.

What Was Measured

The subject headings attached to it are Cardiovascular Diseases, Cholecalciferol, Dietary Supplements, Finland, Neoplasms, Vitamin D and Vitamin D Deficiency.

Author keywords: cancer, elderly, randomized controlled trial and supplementation study.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 2495 participants.

With several hundred people or more, it is a fairly large study for this kind of research.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2022 (The American journal of clinical nutrition), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.